BioCentury
ARTICLE | Clinical News

Accelr8 reports data for pneumonia diagnostic

May 18, 2011 1:09 AM UTC

Accelr8 Technology Corp. (NYSE-A:AXK) reported data from a pilot trial of its BACcel rapid diagnostic system to analyze 77 bronchoalveolar lavage (BAL) samples from 35 ICU patients at high-risk of developing pneumonia. BACcel had 86% sensitivity and 97% specificity for detecting any of the three target bacterial organisms -- methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Acinetobacter species. Furthermore, the results were reported within 4-6 hours after the lab received a specimen, which the company said is 40-66 hours faster than culturing. Data were presented at the American Thoracic Society meeting in Denver. ...